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Sequential study of the IgA system in relapsing IgA nephropathy.
Cellular and immunochemical parameters of the lgA system were
studied in 15 subjects with IgA nephropathy (IgAN) and 15 age—
matched controls. In IgAN remission no abnormalities of the igA
system were detectable by the methods used. In IgAN relapse, [mac-
roscopic hematuria associated with upper respiratory tract infection
(URTI) (N 6)1 there were rises in IgA-bearing B-lymphocytes (three
of six), T helper/suppressor cell ratio (six of six) and pokeweed
mitogen—induced IgA production (four of six). Total serum and salivary
IgA were unchanged. Serum IgA profile (HPLC-ELISA) showed in-
creases in polymer IgA (three of six). No such changes were found
during URTI in controls. These lindings support the view that an
exaggerated IgA response to mucosal antigen challenge initiates
glomerular damage and hematuria in IgAN.
Since its first description in 1968 [1], IgA nephropathy (IgAN)
has become a well recognized clinicopathological entity [2]. Its
most characteristic clinical setting is recurrent macroscopic
hematuria in children and young adults, hematuria often occur-
ring within 12 to 24 hours of the onset of upper respiratory tract
or gastrointestinal infection. The coincidence of macroscopic
hematuria with infection at mucosal surfaces suggests that an
abnormal mucosal immune response may precipitate glomeru-
lar damage. Polymer IgA (consisting of dimer and higher
polymers) is produced at mucosal surfaces in response to
antigen challenge. Although only a small proportion of serum
IgA is polymer, there is good evidence that glomerular IgA in
IgAN is polymeric, since it contains J chain [3—6] and has the
capacity to bind secretory component (SC) [3, 6, 7], although
SC itself is not found in the kidney [8, 9], Animal models
suggest that the type of mesangial injury seen in IgAN may be
induced by the deposition of circulating antigen—antibody com-
plexes containing IgA (lgA-CIC) [10] or by the accretion of IgA
to antigen already in the mesangium [1111.
Recent studies in IgAN have reported increased levels of
serum polymer IgA [12, 13] and IgA-CIC [14—19], and demon-
strated possible abnormalities in the mechanisms involved in
their production and clearance [20—24]. However, these studies
have been cross—sectional, investigating cohorts of patients at a
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single time point, using patients who may have a range of
clinical manifestations at the time of study. Although some
studies have related IgA immune abnormalities to disease
activity, repeated studies in the same individuals during
changes in clinical state have not been reported. Striking
abnormalities in IgA immunity are most likely to be found when
disease is very active (during bouts of macroscopic hematuria).
Furthermore, the wide variation in many of the parameters
studied, even in healthy controls, creates difficulty in interpret-
ing results when comparing groups, suggesting that sequential
studies of individuals at different stages of disease may be the
most useful way of identifying important disease—related phe-
nomena.
In this study, a homogeneous cohort of children and young
adults with IgAN and recurrent macroscopic hematuria were
studied. They were first analyzed while asymptomatic (remis-
sion) and then were investigated again at the height of macro-
scopic hematuria (relapse). Significant changes in immune
parameters were sought by analyzing paired data for remission
and relapse in the same individual. Results were also compared
to age—matched healthy controls, some of whom were studied
during upper respiratory tract infection.
Methods
Patients
Eight children and seven adults (13 male, two female) with
l)iopSy proven IgAN and recurrent episodes of macroscopic
hematuria were studied. Hematuria had usually (11 of 15) been
precipitated by infection, especially of the upper respiratory
tract (URTI); although in some (four of 15) the precipitating
event was unclear. Age range at onset (first episode of
hematuria) was four to 28 years, and at the time of study was
eight to 33 years. Two clinical states were defined as the
following.
Remission: The patient was symptom free and was normo-
tensive. There was normal renal function (creatinine clearance
>80 rnl/min/i .73 m2, serum creatinine <100 mol/liter) and the
only laboratory evidence of renal disease was persistent micro-
scopic hematuria (13 of 15) and in some (seven of 15) low grade
proteinuria (<1 g/24 hrs).
Relapse: An episode of frank hernaturia. Such episodes
occurred during the study in six subjects. The precipitating
event was URTI (five of six) or gastrointestinal infection (one of
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six). In two of six patients there was a significant transient
decline in renal function, serum creatinine rising from 80 to 115
mol/liter and from 100 to 240 mol/liter, respectively.
Subjects were studied in remission and at the height of a
subsequent relapse (within 24 hrs of onset of hematuria). No
patient had hypertension and none had evidence of systemic
lupus or liver cirrhosis. In no patient had there been clinical
evidence of Henoch—Schonlein purpura.
Controls
Nine age—matched children and six adults (nine male, six
female), age range seven to 33 years, were studied as controls.
Adults were volunteers from laboratory and medical staff,
children were attending general pediatric clinics with conditions
having no immunological or renal component. All controls had
normal urine sediment and normal serum creatinine. Five
controls (age range eight to 32 years) were initially studied
during URTI and subsequently after recovery. Venous blood
and saliva were collected from each subject after an overnight
fast.
Lymphocyte studies
Isolation of peripheral blood lymphocytes. Twenty—five to 30
ml venous blood was transported in preservative free heparin.
The blood was diluted in PBS, overlaid onto Ficoll—Triosil
(Lymphocyte Separation Medium, Flow Labs, Helsinki, Fin-
land) and centrifuged at 400 g for 25 minutes at room tempera-
ture. The mononuclear cells at the interface were harvested and
washed in calcium and magnesium—free Hanks balanced salt
solution (HBSS, Gibco, Grand Island, New York, USA). After
washing, the cells were resuspended in complete HBSS.
Total and differential white cell counts were performed by
fluorescence microscopy after staining with acridine orange.
This and all other fluorescence microscopy used a Leitz Dialux
2OEB microscope (Leitz Inc., Heerbrugg, Switzerland).
Enumeration of lymphocyte subpopulations: a) B lympho-
cytes. B lymphocytes were estimated as surface immunoglob-
ulin bearing cells. One x 106 mononuclear cells were incubated
at 4°C with fluorescein isothiocyanate conjugated (FITC) F
(ab')2 goat antisera to human total immunoglobulin or IgA
(Kallestad) for 30 minutes. (F (ab')2 fragments were used to
avoid non-specific binding to Fc receptors on some cells.) The
cells were washed twice in complete HBSS containing 0.01%
sodium azide, being kept at 4°C throughout. Cells with positive
surface fluorescence were expressed as a percentage of total
lymphocytes seen, and as an absolute value for each subpop-
ulation in the light of the total lymphocyte count.
b) T lymphocytes. T cell subpopulations were recognized on
the basis of surface phenotype defined by monoclonal antibod-
ies using indirect immunofluorescence. One x 106 mononuclear
cells were incubated at 4°C for 30 minutes with 25 pJ of mouse
monoclonal antibody OKT3 (recognizing total T cells), OKT4
(recognizing T helper/inducer cells), or OKT8 (recognizing T
suppressor/cytotoxic cells) (Ortho Pharmaceuticals, Raritan,
New Jersey, USA). Cells were washed at 4°C in HBSS con-
taining 0.01% sodium azide and then incubated for 30 minutes
with FITC goat anti-mouse IgG (Miles Laboratories, Elkhart,
Indiana, USA). After further washing, cells with positive sur-
face fluorescence were counted as a percentage of total lym-
phocytes, and an absolute value for each circulating subpop-
ulation given in the light of the total lymphocyte count. The
balance of circulating immunoregulatory cells was expressed by
the OKT4+/OKT8+ (helper/suppressor) cell ratio.
Pokeweed mitogen—induced immuno globulin production. Af-
ter separation, mononuclear cells were washed six times in
HBSS and resuspended at 1 x l06/ml in tissue culture medium
(RPM! 1640, Flow Labs) with 10% fetal calf serum, penicillin
(100 g/ml), streptomycin (50 g/ml), and buffered by 20 mivi
Hepes and sodium bicarbonate (0.85 g/liter). Two hundred jd(2
x l0 cells) were incubated in round—bottomed multiwell tissue
culture plates (Linbro). Ten d of pokeweed mitogen (PWM,
Gibco Laboratories, Grand Island, New York, USA) was added
to wells in triplicate at dilutions of 1:10, 1:25, 1:50; control wells
received no mitogen. The cells were cultured for one week at
37°C in 5% CO2. Plates were then centrifuged at 400 g for 10
minutes and 150 tl of culture supernatant aspirated from each
well to a fresh well. Supernatants were stored at minus 20°C to
await analysis.
Quantitation of supernatant immunoglobulin (and salivary
IgA and HPLC eluates) was by enzyme—linked immunosorbent
assay (ELISA). Multiwell plates (Dynatech) were coated with
anti-human IgG (Dako, Copenhagen, Denmark), 1gM (Dako),
or IgA (Atlantic) by incubating at 4°C for 18 hours in bicarbon-
ate buffer pH 9.6. Plates were washed in PBS Tween and BSA
1 mg/ml added for one hour to prevent non-specific protein
absorption. Dilutions of PWM culture supernatant (or saliva) in
PBS-BSA-tween were added to 4°C for 18 hours. After wash-
ing, plates were incubated with 1:1000 peroxidase—conjugated
anti-IgG, 1gM and IgA (Dako). Plates were developed by the
addition of ABTS (Sigma Chemical Co., St. Louis, Missouri,
USA) in citrate phosphate buffer pH 5.0 with 0.002% hydrogen
peroxide. Intensity of color generated was read as absorbance
by an automatic plate reader (Multiscan, Flow) with a 420 nm
filter. Standard curves used pooled IgG, 1gM and IgA myeloma
proteins. Results for each immunoglobulin class were ex-
pressed as ng produced per 2 x iO cells using the median of the
triplicate of the 1:25 PWM dilution (this dose of PWM gave the
optimal response in the majority of subjects).
Saliva assays. Saliva specimens were placed at 4°C immedi-
ately after collection, and 0.01% sodium azide was added as
soon as possible. Aliquots were then stored at minus 70°C until
the assays were performed. Total salivary IgA was measured by
ELISA (as described above). Salivary albumin was measured
by single radial immunodiffusion.
Serum immunoglobulins. Serum total IgG, IgA and 1gM were
measured by laser nephelometry using a Beckman Auto ICS
nephelometer (Beckman Instruments, Fullerton, California,
USA).
High performance liquid chromatography (HPLC). HPLC
was used in conjunction with ELISA to analyze IgA monomer
and polymers in serum [25].
Molecular sieving HPLC was performed using a TSK 4000
SW column connected via a guard column to an HPLC pump
(LKB). Flow rate was 0.4 ml/min using 0.1 M sodium phosphate
buffer pH 6.8. Serum diluted 1:20 was passed through a 1 ifilter
(Millipore Corp., Bedford, Massachusetts, USA) and a 40 tl
sample injected on to the column. Fractions were collected
from the column and transferred to multiwell plates (Dynatech)
for analysis by ELISA.
The ELISA plates were coated with goat anti-human IgA
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(Atlantic) and incubation with the column fraction was followed
by peroxidase—conjugated anti-human igA (Dako). Two plates
were used for each run. On one a monomer IgA standard curve
was used with 10 d eluate per well. A second plate was
optimized for polymer IgA using a polymer lgA standard curve
and 20 .d eluate per well.
IgA monomer and polymer standards were prepared using
sera from five patients with IgA myelomatosis (three were IgA
A, two IgA ) which contained both monomer and dimer species
as shown by HPLC and ELISA. Sera were fractionated by
ammonium sulphate precipitation and DEAE chromatography,
and IgA was size fractionated into monomer and dimer species
by HPLC. Separate monomer and dimer standards were pro-
duced by pooling the purified components from the five sera.
The standard preparations were shown by ELISA to be free of
IgG and 1gM and were assayed for protein content by the
Lowry method.
Serum complement Components. Total hemolytic comple-
ment activity (CH5O) was measured by timed lysis of sensitized
sheep red blood cells. C3, C4 and factor B were measured by
laser nephelometry and Clq by radial immunodiffusion. C3
breakdown products were measured by immunoelectrophoresis
and immunofixation.
Statistical methods
Parametric data are tabulated as mean SEM, and non-
parametric data as median with ranges. Comparison of means
used Student's t-test (for parametric data) and Mann—Whitney
test (for non-parametric data).
Results
Lymphocyte subpopulalions
In remission IgAN subjects did not differ from controls in
percentage or absolute numbers of T helper, T suppressor, total
B, or lgA-B cells (Table 1).
Paired data for changes in lymphocyte subpopulations in
IgAN relapse and control URTI are shown in Table 2.
T lymphocyte subpopuiations. There was a significant in-
crease in helper/suppressor cell ratio in IgAN relapse (2.27
0.45) compared to remission (1.52 0.23) (P < 0.01), paired
f-test), while no such change was seen in control IJRTI (1.60
0.1 vs. 1 .86 0.39). These changes in helper/suppressor cell
ratio are shown in Figure 1. The change in helper/suppressor
cell ratio is predominantly due to a decrease in the T suppressor
subpopulation, although no changes in T cell parameters during
IgAN relapse are statistically significant.
B lymphocyte subpopuiations. Total B cell numbers did not
change in IgAN relapse. There were, however, increases in
percentage and absolute IgA B cell numbers in IgAN relapse,
while during control URTI there were decreases in the same
parameters. However, variations were wide and these shifts
were not statistically significant.
Changes in percentage IgA B cells are shown in Figure 2.
PWM-induced immunoglobulin synthesis. Values for lgG,
IgA, and 1gM in vitro synthesis are shown in Tables 3 and 4.
Results are given for unstirnulated cultures and with the addi-
tion of PWM (1:25), the dose (of three used) which gave the
optimum response under the experimental conditions used.
There were no significant differences between IgAN remission
Table 1. Peripheral blood lymphocyte populations in IgA
nephropathy (remission) and controls (mean SEM)
IgAN
Co
(N
ntrol
15)
remission
(N= 15)
OKT3+
Total T cells, % 68,0 1.4 63.2 3.0
Absolute, x109/Iiter 1.61 9.12 1.37 0.12
OKT4+
T Helper cells, % 43.4 2.7 36.8 2.7
Absolute, x109/liter 1.06 0.10 0.80 0.10
OKTS +
I suppressor, % 28.0 2.0 26.1 1.1
Absolute x109/liter 0.63 0.05 0.56 0.04
OKT4 + /OKT8 +
Helper/suppressor 1.67 0.17 1.48 0.15
Total B cells
Percentage 9.5 1,1 7.6 0.7
Absolute, x109/liter 0.23 0.04 0.15 0.01
IgA-B cells
Percentage 2.10 0.17 1.95 0.24
Absolute xlIP/ljter 43.1 4.1 45.4 7.6
and controls. IgA production (stimulated or unstimulated) did
not increase significantly in the group in IgAN relapse as a
whole, although there were marked increases in two subjects
and individuals with IgAN were more likely to have increased
PWM-stimulated IgA production (four of six) compared to
controls during URTI (two of five) (Fig. 3). There were no
significant changes in IgG or 1gM production.
Serum imrnunoglobulins. Total serum lgG and 1gM were
normal in all study groups. In IgAN remission total serum IgA
was 2.5 (1.5—5.8) g/liter. Adult normal range in the laboratory
performing the assays was 0.6—3.3 g/liter. However, IgA levels
are low in childhood and only slowly increase to adult levels
during the second decade of life. Eight of the 15 IgAN subjects
had serum IgA levels above the age—corrected normal range.
During IgAN relapse or control URTI levels did not change
significantly in any individual.
Serum complement components. C3, C4, Clq and Factor B
were normal in IgAN remission and controls, and remained so
in relapse and control URTI, giving no evidence of widespread
complement activation. C3 breakdown products were not de-
tected.
Serum IgA profile. Using HPLC-ELISA analysis the majority
of IgA (>90%) in normal serum appears as monomer preceded
by much smaller peaks of dimer and higher polymers, which in
some subjects may be undetectable. Figure 4 shows the poly-
mer IgA profile in fasting serum in one control subject and in
three subjects with IgAN during remission and relapse. In the
control and in remission in one IgAN subject, dimer and
polymer peaks were barely detectable, although they were
clearly seen in the other two IgAN subjects in remission. In
relapse in all three IgAN subjects there were striking increases
in dimer and higher IgA polymers. Such increases in polymer
IgA were not seen in three other IgAN relapses or during
control URTI. Two of the three subjects with detectable
increases in polymer TgA were those whose relapses were
severe enough to cause a transient decline in renal function.
Salivary IgA. Total salivary IgA was corrected for dilution
variation by expressing results as a ratio IgA/albumin. This
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Table 2. Changes in peripheral blood lymphocyte populations during IgAN relapse and control URTI (paired data
OKT3 + (Total T cell)
%
Absolute, x 10°/liter
OKT4 + (T helper cell)
%
Absolute, x 10°/liter
OKT8 + (T suppressor cell)
%
Absolute, x 10°/liter
OKT4 +/OKT8 +
Helper/suppressor
Total B cells
%
Absolute X 10°/liter
lgA-B cells
%
Absolute x 10°/liter
a Mean + SEM
° P < 0.01 (paired t-test)
66.1 1.8
1.52 0.33
43.4 3.9
0.96 0.16
26.3 3.9
0.66 0.24
1.86 0.39
6.9 1.0
0.12 0.03
2.24 0.21
50.0 8.9
Controls gA nephropathy
ratio was not significantly different in IgAN (11.1 2.6)
compared to controls (7.9 2.4), and did not change in IgAN
relapse (12.7 4.2). In control URTI the ratio was lower (2.8
0.6), but the data is from four subjects only.
Discussion
Recurrent episodes of macroscopic hematuria are character-
istic of IgAN. Such hematuria is often precipitated by mucosal
(respiratory or gastrointestinal) infection [21. Since IgA has a
major role in mucosal immunity, it has been proposed that an
abnormal IgA mucosal immune response during such infections
70.6 2.4
1.48 0.41
45.0 5.1
0.89 0.13
29.3 3.7
0.62 0.20
1.60 0.19
9.4 1.5
0.19 0.05
1.31 0.29
27.8 11
Remission
66.7 5.4
1.46 0.21
40.7 4.8
0.93 0.18
27.6 1.6
0.61 0.07
1.52 0.23
8.9 1.2
0.18 0.03
2.27 0.48
53 14
Relapse
65.1 6.2
1.47 0.1
44.5 5.8
0.89 0.09
22.4 3.5
0.46 0.08
2.27 0.45°
6.6 0.8
0.23 0.08
3.27 1.0
71.8 24
in patients with IgAN predisposes to mesangial IgA deposition
and glomerular hematuria. This hypothesis is endorsed by the
finding that mesangial IgA in IgAN is polymeric [3—7], since it is
known that mucosal IgA is polymeric, whereas the majority of
serum IgA is monomeric.
Previous studies have sought abnormalities in parameters of
the IgA immune system in IgAN, and although findings have
not always been consistent, a number of abnormalities have
been described.
Increased numbers of circulating IgA-B cells have been
reported in IgAN [24] but this could not be confirmed when
more rigorous methodology used F(ab')2 anti-IgA antibodies
(eliminating non-specific Fc binding) to define IgA positive cells
[26, 27]. Recently, enumeration of plasma cells in lymphoid
tissue (using tonsillectomy specimens) showed an increase in
IgA producing cells in IgAN [28, 29]. Circulating T cell subpop-
ulations may also be abnormal in IgAN with increased
helper/suppressor ratio [20, 30, 311. The possibility that this
altered T cell ratio influences IgA production is supported by
findings of increased T alpha cells and abnormal IgA-specific T
cell help and suppression in IgAN [20, 23, 32], However, IgA
production from lymphocyte culture using pokeweed mitogen
(PWM) (a T cell—dependent stimulus producing IgA which is
predominantly polymeric 33]) has been variably reported as
normal [27] or increased [20, 21] in IgAN; limited evidence has
not associated changes in in vitro IgA production with disease
activity in IgAN [27].
There is evidence that circulating total and polymeric IgA
may be abnormal in IgAN. An increase in total serum IgA is
reported in 30 to 60% of patients with IgAN 116, 27, 34—36].
However 90% of circulating IgA is monomeric, and changes in
polymer IgA may not be reflected in total IgA levels, increased
polymer IgA in absolute levels and also as a percentage of total
serum IgA has been reported [12, 13] but not confirmed by
others [15, 37—39]. Some workers [12] measured IgA by com-
petitive inhibition radioimmunoassay in fractions from gel fil-
tration or sucrose density ultracentrifugation. Unfortunately,
Control (N = 5)
Healthy URTI
lgAN (N = 6)
4.0 -
3.5 —
3.0—
2.5 —
I—
0 2.0-
0
1.5 —
1.0
0.5
0 Healthy URTI
Fig. 1. OKT4/OKT8 ratios in control URTI and IgA nephropathy.
Remission Relapse
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Healthy URTI Remission Relapse
Fig. 2. Percentage IgA-B cells in control URTI and IgA nephropathy.
this type of radioimmunoassay is known to overestimate poiy-
mer IgA [40].
Cross—sectional studies in IgAN show increased IgA-CIC by
a number of assays, including the conglutinin binding assay [14,
15], Raji cell assay [15—18], and anti-IgA inhibition assay [17,
191. However the conglutinin assay has also been found nega-
tive [361. Some groups report an association between the level
of CIC and disease activity, exemplified by macroscopic
hematuria [14, 17, 371, others do not [15]. CIC, particularly
those containing IgA, increase after food in healthy subjects
[41] and this response may he exaggerated in patients with
glomerular disease, including IgAN [42]. Of all studies of CIC in
IgAN, only one [17] states that CIC were assayed in fasting
serum samples, so that findings of raised lgA-CIC levels must
be interpreted with caution.
Inconsistencies in the IgA immune system abnormalities
found in IgAN may have some basis in methodological varia-
tions described above. However, variability in patient selection
and study design may also contribute. IgAN is a clinically
heterogeneous disease; some patients have hypertension, renal
impairment and proteinuria, and are not prone to recurrent
macroscopic hematuria. Such patients may be at a later stage of
disease evolution when immune mechanisms are less relevant
to the persistence and progression of their renal disease. If IgA
immune system abnormalities have major importance in IgAN,
such abnormalities may best be demonstrated during episodes
of macroscopic hematuria. Associations between immune ab-
30 —
20 —
10—
0
Fig. 3. PWM siimulated IgA production in control URTI and IgA
nephropathy.
IgA
Control
N=15 nephropathyN=14
lgA
unstimulated 10.1 (2.0—38.5) 8.3 (3.5—38.7)
PWM1:25 15.9 (1,5—48.3) 15.2 (4.0—239)
lgG
unstimulated 26.2 (12.6—37.7) 22.1 (1.0—87.4)
PWM1:25 35.5 (16.4—123) 34.2 (1.0—203)
1gM
unstimulated 12.3 (5.1—46) 10.8 (1.0—28.1)
PWMI:25 27.0 (1.0—221) 34.6 (2.0—200)
normalities and disease activity in IgAN have been reported but
only on the basis of cross—sectional studies where individuals
have been studied once, Immune parameters have wide biolog-
ical variation even in healthy populations so that demonstrating
significant differences with disease activity in such cross—
sectional analyses may be difficult.
The present study was designed to overcome these diffi-
culties. A homogeneous cohort of 1gAN subjects with typical
recurrent hematuria was selected. Patients with hypertension,
heavy proteinuria or renal impairment were excluded, as were
patients with systemic diseases associated with mesangial lgA
deposition (particularly SLE and cirrhosis). These may modify
immunity, and it is possible in these entities that IgA deposition
in the kidney occurs through different immunopathogenic
mechanisms. Cases of Henoch—SchOnlein purpura were also
excluded from the study. When pathogenic mechanisms are
better defined, Henoch—Schönlein purpura and IgAN may
prove to be part of the same spectrum of disease; but until such
mechanisms are known, differences in age of onset, systemic
Controls IgA nephropathy
S
Controls IgA nephropathy
. (230)100 -
90 -
80 —
70 —
60 -
50 —
40 -
(0
(0U
6.0
5.5
5.0
4.5
4.0
3,5
U,
0)U
3.04
2.5
2.0
1.5
1.0
0.5
0—
SS
Healthy URTI
Table 3. in vitro immunoglobulin synthesis by peripheral blood
lymphocytes in IgA nephropathy (remission) and controls, median
(range) ng/2 X iO cells
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Table 4. In vitro immunoglobulin synthesis by peripheral blood lymphocytes in IgA nephropathy relapse and control URTI (paired data),
median (range) ng/2 X 10 cells
Control N = 15 IgAN N = 6
Remission RelapseHealthy URTI
IgA
unstimulated
PWM 1:25
IgG
unstimulated
PWM 1:25
1gM
unstimulated
PWM 1:25
13.7 (2.5—38.5)
17.4 (1.5—48.3)
27.8 (22.3—37.7)
35.9 (22.8—66.4)
19.1 (7.4—23.1)
37.2 (30.8—77.6)
12.3 (6.4—74.3)
13.0 (5.5—61.9)
19.3 (13.5—44.7)
26.0 (16.7—146)
9.0 (1.0—67.7)
21.2 (0.5—203)
10.1 (3.5—33.9)
12.3 (4.0—38.2)
26.1 (3.0—66.2)
23.2 (1.0—79.8)
13.7 (6.3—46.0)
21.4 (1.0—94.1)
12.0 (1.0—57)
18.0 (1.0—84.2)
22.9 (11.1—50.1)
26.1 (7.5—102)
13.5 (7.6—47.6)
28.5 (9.3—201)
Fig. 4. HPLC-ELISA serum IgA profile in one
control (1) and three subjects with IgAN (2-4)
in remission (—) and relapse (---). Dimer and
higher polymer IgA peaks are seen in two
IgAN subjects (2, 4) in remission but are
barely detectable in the control (1) and one
IgAN remission (3). Increases in polymer IgA
are seen in all three IgAN relapses (2—4).
involvement, and association with intercurrent infection justify
their separation.
Patients were studied in remission and compared to
age—matched controls, and some IgAN subjects were subse-
quently studied in relapse at the height of macroscopic
hematuria, when maximum IgA immune abnormality might be
expected. The significance of any changes was sought by
comparison with remission data in the same patient by paired
analysis. The possibility that any changes found were a conse-
quence of the intercurrent infection which precipitated the
hematuria, rather than the relapse itself, was investigated by
studying some controls during URTI and making similar com-
parisons of paired data. No such sequential study of IgAN has
previously been reported.
In remission in IgAN we found no significant abnormalities in
IgA system parameters compared to controls. In relapse there
was a significant increase in helper/suppressor T cell ratio (P <
0.01) and increases were also found in percentage and absolute
numbers of IgA-B cells, which were not statistically significant.
In vitro production of IgG and 1gM from lymphocytes stimu-
lated by PWM was not changed in IgAN relapse and control
URTI. However, in IgAN relapse four of six individuals
showed rises in IgA production, and this was particularly
striking in two (Fig. 3). But this was not the case in the two
other IgAN relapses studied, and furthermore two of five
controls with URTI also showed some increase in IgA produc-
tion. A larger study would be required to seek confirmation of
any possible difference between IgAN and controls. The pre-
sent studies were performed using fetal calf serum, and do not
exclude the possibility that a serum factor in IgAN may modify
IgA synthesis in vivo.
In the present study, total serum IgA was increased in IgAN
but did not rise further in relapse. Using HPLC-ELISA, three
of six subjects studied showed clear increases in dimer and
higher polymers of IgA in relapse compared to remission (Fig.
4), although three others had no detectable change in IgA
profile. The HPLC-ELISA technique used does not define with
certainty whether the polymer IgA is aggregated IgA or repre-
sents antigen—antibody complexes in which the antibody moeity
is IgA. Our studies were performed on fasting serum, so that
food—mediated rises in IgA-CIC, which might modify the serum
IgA profile, were excluded.
Studies of salivary IgA were undertaken to see if changes in
circulating IgA were paralleled by changes in the IgA mucosal
system. However, there were no changes in salivary IgA
(corrected for dilution factors using salivary albumin levels) in
IgA during remission or relapse compared to controls. The
great majority of salivary IgA will be secretory IgA (dimer IgA
+ SC), but the assay used in this study does not distinguish
secretory IgA from dimer IgA (without attached SC). It is
p d m p d m p d m p d m
I I I I I I I I I I25
15
5
1 2 3 4
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interesting to speculate that excess of polymer IgA in the serum
may be a reflection of impaired interaction between dimer IgA
produced by mucosal lymphoid tissue in response to antigen
challenge and the SC dependent mechanism which transports
IgA to the mucosal surface, allowing dimer IgA to be freed into
the serum. Such an abnormality might be indicated by abnormal
amounts of free SC and dimer IgA in saliva.
These sequential data support the contention that episodes of
macroscopic hematuria in IgAN are associated with abnormal
activation of the IgA system, while no abnormalities were
detected in the same subjects studied during remission. Such
activation (indicated by increased helper/suppressor T cell
ratio, increased igA-B cells, and increased PWM driven IgA
production) may lead to the increases in circulating polymer
IgA. Recent studies suggest that mesangial IgA in IgAN is
polymeric 3—7], so deposition of such circulating polymer IgA
may be an important mediator of glomerular damage and
hematuria.
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